Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors
| Autor: | Gad Singer, Edgar Dahl, Haike Leibiger, Ronald Simon, Esmeralda Castanos-Velez, Eva Klopocki, Lutz Essers, Arndt Hartmann, Robert Stöhr, Irina Klaman, Birgit Weber, Guido Sauter, Klaus Hermann, Peter J. Wild, André Rosenthal, Glen Kristiansen |
|---|---|
| Předmět: |
CA15-3
Cancer Research Pathology medicine.medical_specialty Colorectal cancer CA 15-3 Down-Regulation Breast Neoplasms Biology medicine.disease_cause Breast cancer medicine Biomarkers Tumor Humans Carcinoma in situ Cancer Membrane Proteins medicine.disease Prognosis Oncology Tumor progression Cancer research Disease Progression Intercellular Signaling Peptides and Proteins Female Carcinogenesis |
| Zdroj: | Europe PubMed Central Scopus-Elsevier |
| Popis: | Aberrant activation of the Wnt signaling pathway plays an important role in the development of solid tumors such as breast and colon cancer. Secreted Frizzled-related protein 1 (SFRP1) is a negative regulator of the Wnt pathway. It has been described that SFRP1 mRNA is strongly down-regulated in breast cancer and a putative tumor suppressor function has been postulated. We have generated and characterized an SFRP1 specific antibody to analyze its expression on protein level and to investigate the association of SFRP1 expression with clinicopathological parameters and patient survival. Analysis of >2000 invasive breast tumors and 56 carcinoma in situ revealed similar frequencies of SFRP1 loss in these tumors (46% and 43% respectively). Therefore, we propose that loss of SFRP1 expression is an early event in breast tumorigenesis. SFRP1 expression was inversely correlated with tumor stage (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|